In one paragraphArticle in Nano letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Hannah C SaffordDepartment of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania19104, United States.ORCID 0000-0002-2512-8153 Hannah C GeislerDepartment of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania19104, United States.ORCID 0000-0001-6455-8183 Ajay S ThatteDepartment of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania19104, United States.ORCID 0000-0001-7372-8893 Kuo-Chieh LiaoGenome Institute of Singapore, Agency for Science, Technology, and Research (A*STAR), Singapore138672, Singapore.
Alexandre PoirierDepartment of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania19104, United States.
Marshall PadillaDepartment of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania19104, United States.
Hannah M YamagataDepartment of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania19104, United States.ORCID 0000-0002-9525-7102 Anushka AgrawalDepartment of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania19104, United States.ORCID 0009-0006-1550-4748 Amanda M MurrayDepartment of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania19104, United States.ORCID 0009-0000-2124-351X Alex G HamiltonDepartment of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania19104, United States.
Kelsey L SwingleDepartment of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania19104, United States.ORCID 0000-0001-8475-9206 Emily FitzgeraldDepartment of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania19104, United States.
Ori ChalomDepartment of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania19104, United States.
Yue WanGenome Institute of Singapore, Agency for Science, Technology, and Research (A*STAR), Singapore138672, Singapore.
Michael J MitchellDepartment of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania19104, United States.ORCID 0000-0002-3628-2244 Funding
mRNA lipid nanoparticles for pre-eclampsiaR01HD115877 · NICHD · UNIVERSITY OF PENNSYLVANIA · PI Michael J Mitchell · 2024 to 2026
$1.0MAmerican Cancer Society Research Scholar Grant NABurroughs Wellcome Fund Career Award at the Scientific Interface NANational Institutes of Health (NICHD R01 HD115877) NANational Institutes of Health (NIH) Director's New Innovator Award NANational Science Foundation NANational Science Foundation (NSF) CAREER Award NANICHD NIH HHS R01 HD115877
6 · The paper itselfAbstract
The placenta has emerged as a promising target for RNA lipid nanoparticle (LNP)-based therapies to treat obstetric complications, yet efficient extrahepatic RNA transfection remains a challenge. Here, we identify innate immune signaling as a regulator of placental RNA translation and demonstrate that inhibition of IFN-α/β receptor (IFNAR) and JAK-STAT signaling enhances LNP-mediated transgene expression in the placenta for both messenger RNA (mRNA) and circular RNA (circRNA). While a placenta-tropic LNP enabled robust and durable circRNA expression in trophoblasts in vitro, circRNA translation was substantially decreased in vivo compared to mRNA in pregnant mice. Inhibition of IFNAR-JAK-STAT signaling enhanced circRNA translation up to 12-fold in maternal organs and increased circRNA and mRNA translation in the placenta up to 17.5- and 4-fold, respectively. JAK-STAT inhibition also enhanced translation of therapeutically relevant VEGF-encoding circRNA and mRNA in pregnant mice, suggesting innate immune modulation as a broadly applicable strategy to improve RNA therapeutics during pregnancy.
Indexed as
NanoparticlesPlacentaReceptor, Interferon alpha-betaRNA, CircularRNA, MessengerAnimalsFemaleHumansImmunity, InnateJanus KinasesLipidsLiposomesMicePregnancySignal TransductionSTAT Transcription FactorsJanus KinasesLipid NanoparticlesLipidsLiposomesReceptor, Interferon alpha-betaRNA, CircularRNA, MessengerSTAT Transcription Factorscircular RNAinnate immune signalinglipid nanoparticlesmRNAplacenta
Identifiers
PMID42677371
PMCPMC13523734
What OpenQuestion holds
Textmetadata
Read underepoch 390